Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQVZJD)

• Drug Name: Enoximone Drug Info
• Synonyms: ENOXIMONE; Perfan; 77671-31-9; Fenoximone; Enoximonum [Latin]; MDL-17043; Enoximona [Spanish]; MDL 17,043; UNII-C7Z4ITI7L7; MDL-17,043; RMI-17043; 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one; C7Z4ITI7L7; 4-Methyl-5-(p-(methylthio)benzoyl)-4-imidazolin-2-one; CHEMBL249856; 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-; NCGC00015400-02; Enoximonum; Enoximona; 1,3-Dihydro-4-methyl-5-[4-methylthiobenzoyl]-2H-imidazol-2-one; DSSTox_RID_80702; DSSTox_CID_25147; DSSTox_GSID_45147; Perfane; Enoximona; E 1279; Perfan (TN); Enoximone (USAN/INN); Enoximone [USAN:BAN:INN]; 1,3-Dihydro-4-methyl-5-(4-methylthiobenzoyl)-2H-imidazol-2-one; FENOXIMONE

Indication

Disease Entry	ICD 11	Status	REF
Congestive heart failure	BD10	Approved	[1]

• Therapeutic Class: Cardiotonic Agents
• Cross-matching ID:
  PubChem CID: 53708
  ChEBI ID: CHEBI:135010
  CAS Number: CAS 77671-31-9
  TTD Drug ID: DMQVZJD

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 3 (PDE3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[4]
Oxtriphylline	DMLHSE3	Cough	MD12	Approved	[4]
Ibudilast	DM4LSPN	Castleman's disease	4B2Y	Approved	[5]
Olprinone	DMWBQKU	Heart failure	BD10-BD13	Approved	[6]
Inamrinone Lactate	DMRMFP4	Cardiac disease	BA00-BE2Z	Approved	[7]
Milrinone	DM8TUPF	Congestive heart failure	BD10	Approved	[4]
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[8]
Tipelukast	DMS9BDQ	Asthma	CA23	Phase 2	[9]
RPL-554	DMLD4VQ	Allergic rhinitis	CA08.0	Phase 2	[10]
Org-30029	DMDZ4R2	Heart failure	BD10-BD13	Phase 2	[11]

Drug(s) Targeting Phosphodiesterase 3A (PDE3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[12]
Aminophylline	DML2NIB	Bronchial asthma	CA23	Approved	[13]
Anagrelide	DMSQ8MD	Thrombocythemia	3B63	Approved	[14]
VESNARINONE	DMBKX3C	Cardiac failure	BD10-BD13	Approved	[15]
BEMORADAN	DMUL6GY	Heart failure	BD10-BD13	Phase 2	[16]
CI-930	DMADPQX	N. A.	N. A.	Discontinued in Phase 2	[17]
EMD-53998	DMVS8IE	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 1	[16]
IMAZODAN	DMWTFO3	N. A.	N. A.	Terminated	[18]
LAS-31180	DMW2K1L	Heart failure	BD10-BD13	Terminated	[19]
BMY-20844	DMDPJ8M	N. A.	N. A.	Terminated	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 3 (PDE3)	TTZCG4L	NOUNIPROTAC	Modulator	[2]
Phosphodiesterase 3A (PDE3A)	TT06AWU	PDE3A_HUMAN	Inhibitor	[3]

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
• [3] Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
• [6] Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
• [7] Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
• [8] The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
• [9] Company report (MediciNova)
• [10] Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.
• [11] Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606.
• [12] A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
• [13] Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
• [14] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
• [15] Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [17] Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
• [18] 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
• [19] Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
• [20] Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. J Med Chem. 1992 Jul 10;35(14):2688-96.